• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oculis Holding AG - Ordinary shares (NQ:OCS)

    12.32 -0.29 (-2.30%)
    Streaming Delayed Price Updated: 3:44 PM EDT, Jul 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 218,311
    Open 12.43
    Bid (Size) 12.17 (700)
    Ask (Size) 12.47 (200)
    Prev. Close 12.61
    Today's Range 12.13 - 12.76
    52wk Range 10.52 - 34.48
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
    From Pomerantz LLP
    Via GlobeNewswire

    Performance

    YTD
    -38.4%
    -38.4%
    1 Month
    +7.6%
    +7.6%
    3 Month
    -55.0%
    -55.0%
    6 Month
    -48.3%
    -48.3%
    1 Year
    -31.0%
    -31.0%

    More News

    Read More
    News headline image
    OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
    From Pomerantz LLP
    Via GlobeNewswire
    Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
    From Pomerantz LLP
    Via GlobeNewswire
    Which stocks are experiencing notable movement on Monday? ↗
    Via Chartmill
    Which stocks are moving on Monday? ↗
    Via Chartmill
    Monday's session: gap up and gap down stocks ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals ↗
    Via MarketBeat
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Reports Q1 2026 Financial Results and Provides Company Update
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
    From Oculis Holding AG
    Via GlobeNewswire
    News headline image
    Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
    From Oculis Holding AG
    Via GlobeNewswire

    Frequently Asked Questions

    Is Oculis Holding AG - Ordinary shares publicly traded?
    Yes, Oculis Holding AG - Ordinary shares is publicly traded.
    What exchange does Oculis Holding AG - Ordinary shares trade on?
    Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Oculis Holding AG - Ordinary shares?
    The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market
    What is the current price of Oculis Holding AG - Ordinary shares?
    The current price of Oculis Holding AG - Ordinary shares is 12.32
    When was Oculis Holding AG - Ordinary shares last traded?
    The last trade of Oculis Holding AG - Ordinary shares was at 07/17/26 03:44 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.